Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
October 18, 2024 09:06 ET
|
Can-Fite BioPharma Ltd.
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M Ramat Gan, Israel, Oct. 18, 2024 (GLOBE NEWSWIRE) --...
Blue Mountain Announces Launch of Blue Mountain University: A Premier e-Learning Experience for RAM Software Users
October 16, 2024 09:00 ET
|
Blue Mountain
Blue Mountain announces the launch of Blue Mountain University, an eLearning platform for RAM software users to enhance skills, efficiency, and compliance.
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
October 09, 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that...
Curia Commits to SBTi Net-Zero Standard
October 08, 2024 09:00 ET
|
Curia Global, Inc.
Curia today announced its commitment to set near- and long-term greenhouse gas reductions in line with the Science Based Targets initiative (SBTi).
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
October 07, 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
RAMAT GAN, Israel , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs...
Blue Mountain and Apprentice.io Announce Groundbreaking Integration of EAM and MES Technologies, Transforming Asset Performance Management for Life Sciences Manufacturing
October 03, 2024 09:00 ET
|
Blue Mountain; Apprentice.io
Blue Mountain & Apprentice.io announce groundbreaking integration of EAM & MES technologies for life sciences manufacturers.
Monthly information on share capital and company voting rights
October 02, 2024 16:30 ET
|
Cellectis Inc.
PARIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Big4Bio Names David J. Whelan Its New Chief Business Officer
October 02, 2024 07:30 ET
|
BigBio Communications
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BigBio Communications is excited to announce that it is expanding the Big4Bio leadership team with the appointment of David J. Whelan as Chief...
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
September 26, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
September 24, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus